Search

everythinglearnresearchcommunity

for

Search:↓

An imbalance between certain immune cells is linked to a chronic skin condition and may be influenced by obesity, smoking, and autoimmune issues.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

The hydrogel patch helps heal diabetic wounds by releasing a healing agent in response to harmful molecules and improving skin regeneration.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

Doctors need more training in skin cancer screening, a new treatment is effective for a skin condition, better diagnosis methods for skin cancer are available, hair loss in women may be linked to hormones and cholesterol, certain skin care products might cause hair loss, babies' skin gets weaker after birth, and a gene mutation might be linked to eczema.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Higher IL-17A levels indicate more severe alopecia areata.

Targeting IL-17 could help treat pattern hair loss.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

T cells and bacteria in the gut and skin help maintain health and protect against disease.

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.

Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.

Skin's Regulatory T cells are crucial for maintaining skin health and could be targeted to treat immune-related skin diseases and cancer.

Special immune cells called Regulatory T cells help control skin inflammation and repair in various skin diseases.

Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.

The conference highlighted new dermatological treatments and emphasized early intervention and addressing conditions lacking evidence-based treatments.

People with alopecia areata often have lower vitamin D levels, which are linked to more severe and longer-lasting hair loss, but vitamin D receptor levels in the skin don't show the same pattern and don't predict treatment success.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

PRP treatment reduces inflammation and increases interleukin-10 in alopecia areata patients.